ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Other Events

ME Staff 8-k
-
0

ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Other Events
Item 8.01 Other Events.

On June13, 2018, the Circuit Court for Oakland County (the “Court”) issued an Order in the matter Rockwell Medical,Inc. v. Robert Chioini and Thomas Klema whereby the Court ordered that the Board of Directors and management of Rockwell Medical,Inc. (the “Company”) not make any material changes to the Company unless first reviewed by the Court; material changes do not include day to day operations of the Company. Any disagreement as to whether an action constitutes a material change will be reviewed by the Court.

The Court also ordered that the Company’s 2018 annual shareholder meeting currently scheduled to be held on Thursday, June21, 2018 at 10:00 a.m.Eastern Time, be adjourned for 30 days. The parties are scheduled to engage in Court-ordered mediation on Tuesday, June19, 2018.

The Court’s Order dated May25, 2018 and the limitations set forth therein (including limitations on the ability of Robert Chioini and Thomas Klema to take certain actions with respect to, or purportedly on behalf of, the Company) remain in effect through Thursday, June21, 2018. The foregoing summaries do not purport to be a complete description of the Court Order dated May25, 2018 and the Court Order dated June13, 2018 and each are qualified in their entirety by reference to the full text of the Court Orders, copies of which are attached hereto as Exhibits 99.1 and 99.2 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits. The following exhibits are being filed herewith:

EXHIBITINDEX


ROCKWELL MEDICAL, INC. Exhibit
EX-99.2 2 a18-15587_1ex99d2.htm EX-99.2 Exhibit 99.2   STATE OF MICHIGAN IN THE CIRCUIT COURT FOR THE COUNTY OF OAKLAND   ROCKWELL MEDICAL INC    Plaintiff,…
To view the full exhibit click here

About ROCKWELL MEDICAL,INC. (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.